An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Equillium Provides Timing Update on Conference Presentations
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
LA JOLLA, Calif.--(BUSINESS WIRE)--
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations.
Equillium will now participate in a virtual fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference on Thursday, February 17, 2022, at 2:20 pm Eastern Time. A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.
Dates for the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research, which were originally scheduled for February have been changed to April 23 – 26, 2022. The conference will take place virtually and in person at the Salt Palace Convention Center in Salt Lake City.
About Equillium Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD) and lupus/lupus nephritis.
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
